C. Victorri-vigneau, E. Dailly, G. Veyrac, and P. Jolliet, Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey

, Br J Clin Pharmacol, vol.64, pp.198-209, 2007.

K. J. Holm and K. L. Goa, Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia, Drugs, vol.59, pp.865-889, 2000.

T. G. Bruun, Abuse potential during use and withdrawal psychosis after treatment with the hypnotic zolpidem

, Ugeskr Laeg, vol.155, pp.2711-2713, 1993.

C. Victorri-vigneau, M. Gé-rardin, M. Rousselet, M. Guerlais, and M. Grall-bronnec, An update on zolpidem abuse and dependence, J Addict Dis, vol.33, pp.15-23, 2014.

E. Jouanjus, G. Guernec, M. Lapeyre-mestre, and F. A. Network, Medical prescriptions falsified by the patients: a 12-year national monitoring to assess prescription drug diversion, Fundam Clin Pharmacol, vol.32, pp.306-322, 2018.

J. Bezin, M. Duong, R. Lassalle, C. Droz, and A. Pariente, The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology, Pharmacoepidemiol Drug Saf, vol.26, pp.954-962, 2017.

M. Gérardin, M. Rousselet, P. Caillet, M. Grall-bronnec, and P. Loué, French national health insurance database analysis and field study focusing on the impact of secure prescription pads on zolpidem consumption and sedative drug misuse: ZORRO study protocol, BMJ Open, vol.9, p.31256026, 2019.

S. E. Mccabe, B. T. West, C. J. Teter, and C. J. Boyd, Trends in medical use, diversion, and nonmedical use of prescription medications among college students from 2003 to 2013: Connecting the dots, Addict Behav, vol.39, pp.1176-1182, 2014.

E. Chambost and M. Chappuy, Le Pharmacien Hospitalier et Clinicien, vol.53, issue.4, pp.288-300, 2018.

J. Touchard, P. Sabatier, G. Airagnes, S. Berdot, and B. Sabatier, Consequences of the new zolpidem prescription regulations: a cohort study from the French national healthcare database, Eur J Clin Pharmacol, p.31608425, 2019.

, Mandatory prescription of zolpidem on secure prescription-Enquiry Point-ANSM: National Agency for the Safety of Medicines and Health Products, p.6, 2020.

®. Zolpidem-(edluar and ®. Stilnox, new prescribing and dispensing conditions-Dear Healthcare Professional Letter-ANSM: National Agency for the Safety of Medicines and Health Products, p.6, 2020.

C. Victorri-vigneau, F. Feuillet, L. Wainstein, M. Grall-bronnec, and J. Pivette, Pharmacoepidemiological characterisation of zolpidem and zopiclone usage, New prescription rules halved zolpidem use in France PLOS ONE, vol.69, pp.1965-1972, 2013.

J. Chambonet, P. Barberis, and V. Peron, How long are consultations in French general practice?, European Journal of General Practice, vol.6, pp.88-92, 2000.

A. S. Kesselheim, M. Donneyong, G. J. Dal-pan, E. H. Zhou, and J. Avorn, Changes in prescribing and healthcare resource utilization after FDA Drug Safety Communications involving zolpidem-containing medications, Pharmacoepidemiol Drug Saf, vol.26, pp.712-721, 2017.

C. Victorri-vigneau, M. Marais, G. Veyrac, A. Chaslerie, and J. Pivette, Responsiveness and communication of pharmacovigilance decisions from health authorities to health professionals: examples of pergolide and celecoxib, Therapies, vol.62, pp.513-517, 2007.

J. Brett and B. Murnion, Management of benzodiazepine misuse and dependence, Aust Prescr, vol.38, pp.152-155, 2015.

C. Victorri-vigneau, G. Basset, and P. Jolliet, How a novel programme for increasing awareness of health professionals resulted in a 14% decrease in patients using excessive doses of psychotropic drugs in western France, Eur J Clin Pharmacol, vol.62, p.16506046, 2006.

A. Benard, S. Billioti-de-gage, P. Cavalié, K. Chatila, and C. Collin, , p.6, 2017.

L. Shukla, S. Bokka, T. Shukla, A. Kandasamy, and P. Chand, Z-Drug" Dependence: Data From a Tertiary Care Center, Prim Care Companion CNS Disord, vol.19, pp.0-0, 2017.

G. K. Jasuja, J. I. Reisman, R. S. Weiner, M. L. Christopher, and A. J. Rose, Gender differences in prescribing of zolpidem in the Veterans Health Administration, Am J Manag Care, vol.25, pp.58-65, 2019.

M. Pourshams and S. K. Malakouti, Zolpidem abuse and dependency in an elderly patient with major depressive disorder: a case report, Daru, vol.22, p.54, 2014.

S. Spyridi, I. Diakogiannis, J. Nimatoudis, A. Iacovides, and G. Kaprinis, Zolpidem dependence in a geriatric patient: a case report, J Am Geriatr Soc, vol.57, pp.1962-1963, 2009.

C. Victorri-vigneau, G. Basset, M. Bourin, and P. Jolliet,

, Therapie, vol.58, pp.425-430, 2003.

F. Schifano, S. Chiappini, J. M. Corkery, and A. Guirguis, An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions, Int J Neuropsychopharmacol, vol.22, pp.270-277, 2019.

Y. Jang, I. Song, I. Oh, and J. Shin, Twelve-year trend in the use of zolpidem and physicians' non-compliance with recommended duration: a Korean national health insurance database study, Eur J Clin Pharmacol, vol.75, p.30280207, 2019.

Y. Schonmann, O. Goren, R. Bareket, D. Comaneshter, and A. D. Cohen, Chronic hypnotic use at 10 years-does the brand matter?, Eur J Clin Pharmacol, vol.74, p.30090968, 2018.

R. Grilli, N. Freemantle, S. Minozzi, G. Domenighetti, and D. Finer, Mass media interventions: effects on health services utilisation, Cochrane Database Syst Rev, vol.000389, 2000.

L. Bou-karroum, F. El-jardali, N. Hemadi, Y. Faraj, and U. Ojha, Using media to impact health policy-making: an integrative systematic review, Implement Sci, vol.12, p.28420401, 2017.

S. Woloshin, L. M. Schwartz, S. Dejene, P. Rausch, and G. J. Dal-pan, Media Coverage of FDA Drug Safety Communications about Zolpidem: A Quantitative and Qualitative Analysis, J Health Commun, vol.22, pp.365-372, 2017.